Targeting ECM-integrin interaction with liposome-encapsulated small interfering RNAs inhibits the growth of human prostate cancer in a bone xenograft imaging model

Kristen Bisanz, Jie Yu, Magnus Edlund, Bill Spohn, Mien Chie Hung, Leland W K Chung, Chia Ling Hsieh

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

The intricate intracellular communication between stromal and epithelial cells, which involves cell-cell-, cell-insoluble extracellular matrix- (ECM), and cell-soluble factor-mediated signaling processes, is an attractive target for therapeutic intervention in hormone-refractory and bone-metastatic prostate cancer. In the present study we demonstrated that androgen-independent PC3 prostate cancer cells adhered to and migrated on vitronectin (VN), a major noncollagenous ECM in mature bone, through the expression of αv-containing integrin receptors αvβ1 and αvβ5 on the cell surface, as determined by antibody function blocking assay and flow cytometry analysis. Small interfering RNAs (siRNAs) targeting human integrin αv markedly reduced their respective mRNA and protein expression in cells, resulting in nearly complete reduction in VN-mediated cancer progression in vitro. In vivo quantitative bioluminescence analysis of human prostate cancer bone xenografts demonstrated for the first time that intratumoral administration of liposome-encapsulated human αv-siRNAs significantly inhibits the growth of luciferase-tagged PC3 tumors in skeleton, which was associated with decreased integrin αv expression and increased apoptosis in tumor cells. This integrin-based gene therapy is particularly suitable for the treatment of prostate cancer bone metastasis.

Original languageEnglish
Pages (from-to)634-643
Number of pages10
JournalMolecular Therapy
Volume12
Issue number4
DOIs
Publication statusPublished - Oct 2005
Externally publishedYes

Fingerprint

Heterografts
Integrins
Liposomes
Small Interfering RNA
Extracellular Matrix
Prostatic Neoplasms
Bone and Bones
Growth
Vitronectin
Bone Neoplasms
Vasopressin Receptors
Neoplasms
Blocking Antibodies
Stromal Cells
Luciferases
Skeleton
Genetic Therapy
Androgens
Flow Cytometry
Epithelial Cells

Keywords

  • Bioluminescence
  • Extracellular matrix
  • Integrins
  • Noninvasive imaging
  • Prostate cancer bone metastasis
  • Small interfering RNA

ASJC Scopus subject areas

  • Molecular Biology

Cite this

Targeting ECM-integrin interaction with liposome-encapsulated small interfering RNAs inhibits the growth of human prostate cancer in a bone xenograft imaging model. / Bisanz, Kristen; Yu, Jie; Edlund, Magnus; Spohn, Bill; Hung, Mien Chie; Chung, Leland W K; Hsieh, Chia Ling.

In: Molecular Therapy, Vol. 12, No. 4, 10.2005, p. 634-643.

Research output: Contribution to journalArticle

Bisanz, Kristen ; Yu, Jie ; Edlund, Magnus ; Spohn, Bill ; Hung, Mien Chie ; Chung, Leland W K ; Hsieh, Chia Ling. / Targeting ECM-integrin interaction with liposome-encapsulated small interfering RNAs inhibits the growth of human prostate cancer in a bone xenograft imaging model. In: Molecular Therapy. 2005 ; Vol. 12, No. 4. pp. 634-643.
@article{087b34276c9e48f7bc15e7b2cbcf27fe,
title = "Targeting ECM-integrin interaction with liposome-encapsulated small interfering RNAs inhibits the growth of human prostate cancer in a bone xenograft imaging model",
abstract = "The intricate intracellular communication between stromal and epithelial cells, which involves cell-cell-, cell-insoluble extracellular matrix- (ECM), and cell-soluble factor-mediated signaling processes, is an attractive target for therapeutic intervention in hormone-refractory and bone-metastatic prostate cancer. In the present study we demonstrated that androgen-independent PC3 prostate cancer cells adhered to and migrated on vitronectin (VN), a major noncollagenous ECM in mature bone, through the expression of αv-containing integrin receptors αvβ1 and αvβ5 on the cell surface, as determined by antibody function blocking assay and flow cytometry analysis. Small interfering RNAs (siRNAs) targeting human integrin αv markedly reduced their respective mRNA and protein expression in cells, resulting in nearly complete reduction in VN-mediated cancer progression in vitro. In vivo quantitative bioluminescence analysis of human prostate cancer bone xenografts demonstrated for the first time that intratumoral administration of liposome-encapsulated human αv-siRNAs significantly inhibits the growth of luciferase-tagged PC3 tumors in skeleton, which was associated with decreased integrin αv expression and increased apoptosis in tumor cells. This integrin-based gene therapy is particularly suitable for the treatment of prostate cancer bone metastasis.",
keywords = "Bioluminescence, Extracellular matrix, Integrins, Noninvasive imaging, Prostate cancer bone metastasis, Small interfering RNA",
author = "Kristen Bisanz and Jie Yu and Magnus Edlund and Bill Spohn and Hung, {Mien Chie} and Chung, {Leland W K} and Hsieh, {Chia Ling}",
year = "2005",
month = "10",
doi = "10.1016/j.ymthe.2005.05.012",
language = "English",
volume = "12",
pages = "634--643",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Targeting ECM-integrin interaction with liposome-encapsulated small interfering RNAs inhibits the growth of human prostate cancer in a bone xenograft imaging model

AU - Bisanz, Kristen

AU - Yu, Jie

AU - Edlund, Magnus

AU - Spohn, Bill

AU - Hung, Mien Chie

AU - Chung, Leland W K

AU - Hsieh, Chia Ling

PY - 2005/10

Y1 - 2005/10

N2 - The intricate intracellular communication between stromal and epithelial cells, which involves cell-cell-, cell-insoluble extracellular matrix- (ECM), and cell-soluble factor-mediated signaling processes, is an attractive target for therapeutic intervention in hormone-refractory and bone-metastatic prostate cancer. In the present study we demonstrated that androgen-independent PC3 prostate cancer cells adhered to and migrated on vitronectin (VN), a major noncollagenous ECM in mature bone, through the expression of αv-containing integrin receptors αvβ1 and αvβ5 on the cell surface, as determined by antibody function blocking assay and flow cytometry analysis. Small interfering RNAs (siRNAs) targeting human integrin αv markedly reduced their respective mRNA and protein expression in cells, resulting in nearly complete reduction in VN-mediated cancer progression in vitro. In vivo quantitative bioluminescence analysis of human prostate cancer bone xenografts demonstrated for the first time that intratumoral administration of liposome-encapsulated human αv-siRNAs significantly inhibits the growth of luciferase-tagged PC3 tumors in skeleton, which was associated with decreased integrin αv expression and increased apoptosis in tumor cells. This integrin-based gene therapy is particularly suitable for the treatment of prostate cancer bone metastasis.

AB - The intricate intracellular communication between stromal and epithelial cells, which involves cell-cell-, cell-insoluble extracellular matrix- (ECM), and cell-soluble factor-mediated signaling processes, is an attractive target for therapeutic intervention in hormone-refractory and bone-metastatic prostate cancer. In the present study we demonstrated that androgen-independent PC3 prostate cancer cells adhered to and migrated on vitronectin (VN), a major noncollagenous ECM in mature bone, through the expression of αv-containing integrin receptors αvβ1 and αvβ5 on the cell surface, as determined by antibody function blocking assay and flow cytometry analysis. Small interfering RNAs (siRNAs) targeting human integrin αv markedly reduced their respective mRNA and protein expression in cells, resulting in nearly complete reduction in VN-mediated cancer progression in vitro. In vivo quantitative bioluminescence analysis of human prostate cancer bone xenografts demonstrated for the first time that intratumoral administration of liposome-encapsulated human αv-siRNAs significantly inhibits the growth of luciferase-tagged PC3 tumors in skeleton, which was associated with decreased integrin αv expression and increased apoptosis in tumor cells. This integrin-based gene therapy is particularly suitable for the treatment of prostate cancer bone metastasis.

KW - Bioluminescence

KW - Extracellular matrix

KW - Integrins

KW - Noninvasive imaging

KW - Prostate cancer bone metastasis

KW - Small interfering RNA

UR - http://www.scopus.com/inward/record.url?scp=25144501954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25144501954&partnerID=8YFLogxK

U2 - 10.1016/j.ymthe.2005.05.012

DO - 10.1016/j.ymthe.2005.05.012

M3 - Article

C2 - 16039164

AN - SCOPUS:25144501954

VL - 12

SP - 634

EP - 643

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 4

ER -